Results of a retrospective study of a racially diverse population demonstrated positive outcomes for patients with NSCLC who experience irAEs when treated with immune checkpoint inhibitors.

A retrospective study revealed differences in metastasis patterns and treatment utilization by ethnicity among patients with breast cancer and brain metastasis.

The median progression-free survival was 6.8 months, and the median overall survival was 19.1 months. Pegylated liposomal doxorubicin (PLD) has demonstrated safety and efficacy in patients with ...

The predictive model demonstrated an 8-year cumulative incidence of TKI failure in the training set of 10% in the low-risk group, 34% in the intermediate risk, and 69% in the high-risk. In the ...

Among patients with early-stage malignant melanoma who underwent standard excision, the incidence of residual melanoma tumor cells in tissue from a wide local excision was low, at less than 5% of ...

All patients receiving surgery/radiotherapy alone or with chemotherapy had improvement or stability of alopecia with LDOM.